Navigation Links
GENova gains access to Big Pharma
Date:9/15/2009

About Bridge BioResearch

Bridge BioResearch is a drug discovery company with the sole corporate focus on Obesity, Type 2 Diabetes and related metabolic disorders. It has research cooperation agreements with leading Research and Development Services providers and bioscience research institutions and universities throughout Asia and Europe. The company uses a cost-efficient technology and patent acquisition strategy for proprietary intellectual property from identified companies, government institutions and universities, paid via milestone-dependent research collaborations and grants. To learn more about Bridge BioResearch, visit www.bridgebioresearch.com.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies such as Pfizer, Amgen , Myriad Genetics, Medarex, and Biogen Idec. Visit GENova online at www.genovabio.com.

Forward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual re
'/>"/>

SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. GENova names Aaron Whiteman as CEO
2. GENova names Dr. John Savin as Vice President
3. Genova files patent for new prostate cancer treatment
4. GENova appoints Dr. Anders Boegh Jensen to Scientific Advisory Board
5. GENova discusses development of new anti-cancer biotechs potentially worth $400 Million per annum
6. GENova appoints Director of Asian business development
7. GENova files patent for new breast cancer treatment
8. GENova to acquire three new drug target patents worth in excess of $1 billion in royalty fees
9. GENova issues clarifying press release
10. GENova appoints Dr. Philip Gould to Scientific Advisory Board
11. GENova appoints Dr. Wang Chong to Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... ... 04, 2015 , ... Bio-Logic Aqua® Research, a fresh water ... only mission and research focus: Water Life Science®. In the current warming and ... is becoming dangerously accelerated. As a result of the global fresh water, water ...
(Date:9/4/2015)... , ... September 04, 2015 , ... ... development of its first neighborhood created specifically for adults with intellectual, developmental and ... Phoenix Metro area and feature 30 cottage or “pocket” homes. In this community, ...
(Date:9/4/2015)... Abilene, Texas (PRWEB) , ... September 04, 2015 , ... Yisrayl Hawkins, Pastor and Overseer ... what he says are prophetic details involving the Pope’s upcoming trip to the United States. ... and details what his role with the Vatican and society is. Yisrayl also provides the ...
(Date:9/3/2015)... ... 2015 , ... AlignLife of Wauwatosa is excited to hold its ... children and adults who don't have the ability to buy a jacket warm enough ... annual Coat Drive to help those in need." , This is AlignLife's third annual ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... Inc. , a privately held medical technology company that will bring low-cost cancer ... markets worldwide. , Preora’s proprietary and automated technology platform detects and measures ...
Breaking Medicine News(10 mins):Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 3Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 2Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 3Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 4Health News:Yisrayl Hawkins Writes Open Letter to Pope Francis In Light of Approaching U.S. Visit 2Health News:AlignLife is Helping to Keep the Community Warm This Winter 2Health News:Preora Diagnostics to Commercialize Cancer Pre-screening Tests 2Health News:Preora Diagnostics to Commercialize Cancer Pre-screening Tests 3
... a world leader in stabilized rice bran (SRB) nutrient ... quarter ended,September 30, 2008., Net revenues for the ... revenues of $1.5 million for the third quarter of ... net revenues from the,Company,s NutraCea segment and $7.8 million ...
... at the 41st Annual Meeting of the American Society of ... ... Inc., a,privately held biopharmaceutical company, will present data indicating that,its therapeutic product ... AC-200, an endogenous human protein,produced by bone cells, was evaluated in a ...
... Labopharm Inc. (TSX: DDS;,NASDAQ: DDSS) today announced that ... of Directors of the Company to fill the ... who has stepped down for personal,reasons. Ms. Selisker ... the,Audit Committee. Ms. Selisker, a Certified Public Accountant, ...
... 7 Hooper Holmes,(Amex: HH ) today announced financial ... For the three months ended September 30, 2008, total ... the third quarter of,2007. The Company recorded a net loss ... per share compared to a net loss of $10.6 million, ...
... Million , Front-End Same-Store Sales Increases 6.0% , ... Margin Improves to 31.3% , Net Loss of $22.3 ... NEW YORK, Nov. 7 Duane Reade Holdings, Inc. today,reported ... Third Quarter Key Highlights, -- Adjusted FIFO EBITDA ...
... Misys (LSE: MSY), the,global application software and services company, ... in a row for its innovative,web-based trade processing solution, ... - at the annual European Banking,Technology Readers, Choice Awards ... Technology,s readers were asked to vote on what they ...
Cached Medicine News:Health News:NutraCea Announces Third Quarter 2008 Financial Results 2Health News:NutraCea Announces Third Quarter 2008 Financial Results 3Health News:NutraCea Announces Third Quarter 2008 Financial Results 4Health News:NutraCea Announces Third Quarter 2008 Financial Results 5Health News:NutraCea Announces Third Quarter 2008 Financial Results 6Health News:NutraCea Announces Third Quarter 2008 Financial Results 7Health News:NutraCea Announces Third Quarter 2008 Financial Results 8Health News:NutraCea Announces Third Quarter 2008 Financial Results 9Health News:Acologix AC-200 Demonstrates Positive Effect on Bone in Preclinical Model of Chronic Kidney Disease 2Health News:Acologix AC-200 Demonstrates Positive Effect on Bone in Preclinical Model of Chronic Kidney Disease 3Health News:Hooper Holmes Announces Third Quarter 2008 Results 2Health News:Hooper Holmes Announces Third Quarter 2008 Results 3Health News:Hooper Holmes Announces Third Quarter 2008 Results 4Health News:Hooper Holmes Announces Third Quarter 2008 Results 5Health News:Hooper Holmes Announces Third Quarter 2008 Results 6Health News:Hooper Holmes Announces Third Quarter 2008 Results 7Health News:Hooper Holmes Announces Third Quarter 2008 Results 8Health News:Duane Reade Holdings, Inc. Reports Third Quarter Results 2Health News:Duane Reade Holdings, Inc. Reports Third Quarter Results 3Health News:Duane Reade Holdings, Inc. Reports Third Quarter Results 4Health News:Duane Reade Holdings, Inc. Reports Third Quarter Results 5Health News:Duane Reade Holdings, Inc. Reports Third Quarter Results 6Health News:Duane Reade Holdings, Inc. Reports Third Quarter Results 7Health News:Duane Reade Holdings, Inc. Reports Third Quarter Results 8Health News:Duane Reade Holdings, Inc. Reports Third Quarter Results 9Health News:Duane Reade Holdings, Inc. Reports Third Quarter Results 10Health News:Duane Reade Holdings, Inc. Reports Third Quarter Results 11Health News:Duane Reade Holdings, Inc. Reports Third Quarter Results 12Health News:Duane Reade Holdings, Inc. Reports Third Quarter Results 13Health News:Duane Reade Holdings, Inc. Reports Third Quarter Results 14Health News:Duane Reade Holdings, Inc. Reports Third Quarter Results 15Health News:Duane Reade Holdings, Inc. Reports Third Quarter Results 16Health News:Duane Reade Holdings, Inc. Reports Third Quarter Results 17Health News:Duane Reade Holdings, Inc. Reports Third Quarter Results 18Health News:Misys Wins 'Best Trade Processing Product' Accolade in European Banking Technology Readers' Choice Awards 2
(Date:9/3/2015)... 2015 About cardiovascular implants ... narrowing or blockage of blood vessels. Cardiac disease ... high cholesterol, and high blood pressure. Coronary artery ... heart failure are some of the major cardiac ... especially coronary arteries, is one of the most ...
(Date:9/3/2015)... , Sept. 3, 2015 Nevro Corp. ... that is providing innovative evidence-based solutions for the treatment ... be presenting at the Morgan Stanley Global Healthcare Conference ... Nevro management is scheduled to present ... via a live audio webcast, accessible in the "Investors" ...
(Date:9/3/2015)... and ALISO VIEJO, Calif. ... (NYSE: AGN ), a leading global pharmaceutical ... medical device company focused on developing ocular implants ... today announced that they have entered into an ... an all-cash transaction.  Under the terms of the ...
Breaking Medicine Technology:Global Cardiovascular Implants Market 2015-2019 2Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 2Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 3Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 4Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 5Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 6
... Science Corporation , a global leader in automated external ... devices, announced today that the Japan Ministry of ... its Powerheart® G3 AED. The company is partnering with ... Omron is a leading healthcare company dedicated to prevention ...
... (Nasdaq: CPHD ) today announced that it will ... 30, 2011, on Thursday, July 21, 2011, after the close ... management presentation at 2 p.m. Pacific Time on Thursday, July ... webcast, please visit Cepheid,s website at www.cepheid.com/investors at ...
Cached Medicine Technology:Cardiac Science Gains Japanese Regulatory Approval for Powerheart AED 2Cardiac Science Gains Japanese Regulatory Approval for Powerheart AED 3Cardiac Science Gains Japanese Regulatory Approval for Powerheart AED 4Cepheid Schedules 2011 Second Quarter Financial Results Announcement and Webcast 2
... of the ELECTRA 1400C are designed to ... walkaway capabilities. This system includes automated primary ... and factor assays in a single setup. ... and automatic preparation of reference curves and ...
... to maximize your testing options even when ... fully automated system offers superior technology, such ... to ensure testing accuracy and efficiency in ... backed by our high-quality service to help ...
... The SYNCHRON CX9 ALX system is ... time-consuming manual processes by as much as ... lower your total costs. Featuring the AccuSense® ... and an expanded test menu, the CX9 ...
... SYNCHRON CX4-S system consolidates DATs, ... in one workstation, targeted to ... 50-200 samples per day. Like ... the CX4-S is easy to ...
Medicine Products: